PEN
Penumbra Inc
NYSE: PEN · HEALTHCARE · MEDICAL DEVICES
$322.23
-0.75% today
Updated 2026-05-08
Market cap
$12.75B
P/E ratio
74.70
P/S ratio
9.08x
EPS (TTM)
$4.34
Dividend yield
—
52W range
$221 – $362
Volume
0.6M
WallStSmart proprietary scores
64
out of 100
Grade: C+
Hold
Investment rating
8.7
Growth
A7.8
Quality
B+6.5
Profitability
B5.3
Valuation
C+4/9
Piotroski F-Score
Moderate
3.8
Altman Z-Score
Safe zone
—
Industry rank
—
View all highly rated stocks (75+) →195 stocks currently score above 75
Price targets
Analyst target
$363.36
+12.76%
12-Month target
$135.82
-57.85%
Intrinsic (DCF)
$340.90
Margin of safety
+0.77%
2 Strong Buy2 Buy13 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Altman Z 3.84 — safe zone
+ Free cash flow $73.30M — positive
+ Revenue growth 22.10% QoQ
Risks
- P/E 74.70x — expensive valuation
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $847.13M | $1.06B | $1.19B | $1.40B | $1.40B |
| Net income | $-2.00M | $90.95M | $14.01M | $177.69M | $32.58M |
| EPS | — | — | — | — | $4.34 |
| Free cash flow | $-74.96M | $82.12M | $147.30M | $174.93M | $73.30M |
| Profit margin | -0.24% | 8.59% | 1.17% | 12.66% | 12.70% |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-04-02 | GREWAL, HARPREET | Sale | 100 | $328.22 |
| 2026-03-15 | YUEN, MAGGIE | Sale | 186 | $336.18 |
| 2026-03-15 | SHIU, LAMBERT | Sale | 150 | $336.18 |
Peer comparison
Smart narrative
Penumbra Inc trades at $322.23. representing a P/E of 74.70x trailing earnings. Our Smart Value Score of 64/100 indicates the stock is good. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of 3.84, it sits in the safe zone. TTM revenue stands at $1.40B. with profit margins at 12.70%. Our DCF model estimates intrinsic value at $340.90.
Frequently asked questions
What is Penumbra Inc's stock price?
Penumbra Inc (PEN) trades at $322.23.
Is Penumbra Inc overvalued?
Smart Value Score 64/100 (Grade C+, Hold). DCF value $340.90.
What is the price target of Penumbra Inc (PEN)?
The analyst target price is $363.36, representing +12.8% upside from the current price of $322.23.
What is the intrinsic value of Penumbra Inc (PEN)?
Based on our DCF model, intrinsic value is $340.90, a +0.8% margin of safety versus $322.23.
What is Penumbra Inc's revenue?
TTM revenue is $1.40B.
Piotroski F-Score?
4/9 — moderate financial health.
Altman Z-Score?
3.84 — safe zone.
Company info
SectorHEALTHCARE
IndustryMEDICAL DEVICES
CountryUSA
ExchangeNYSE
CurrencyUSD
Quick metrics
P/S ratio9.08x
ROE13.80%
Beta0.74
50D MA$333.08
200D MA$296.63
Shares out0.04B
Float0.04B
Short ratio—
Avg volume0.6M
Performance
1 week-0.95%
1 month-2.21%
3 months-5.51%
YTD+3.64%
1 year—
3 years—
5 years—